Proof of Concept for High-Dose Cannabidiol Pretreatment to Antagonize Opioid Induced Persistent Apnea

Version 1. Preprint. 2024 Sep 14.

doi: 10.1101/2024.09.13.612358

PMCID: PMC11419143

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

Beth M. Wiese, Evgeny Bondarenko, and Jack L. Feldman

Abstract

Using a mouse equivalent of FDA-approved cannabidiol (CBD) dosing, we found high dose CBD affects opioid induced persistent apnea (OIPA), the principal cause of opioid related fatalities. CBD pretreatment mitigated respiratory depression from fentanyl in awake mice and significantly delayed OIPA onset in anesthetized mice, effective as the opioid antagonist naloxone. The powerful effect of CBD pretreatment on OIPA suggests a novel therapeutic strategy to reduce fatal opioid overdose incidence.

Go to:

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.

Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

Proof of Concept for High-Dose Cannabidiol Pretreatment to Antagonize Opioid Induced Persistent Apnea

This is a preprint.

Abstract

Full Text Availability

Freedom Wares

Previous PostEdible cannabis for chronic low back pain: associations with pain, mood, and intoxication

Next PostUse of Cannabidiol-Dominant Extract as Co-Adjuvant Therapy for Type 2 Diabetes Mellitus Treatment in Feline: Case Report

Leave a Reply Cancel Reply